Public Sector Pension Investment Board Purchases 520,637 Shares of TG Therapeutics, Inc. $TGTX

TG Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Public Sector Pension Investment Board increased its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 115.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 973,454 shares of the biopharmaceutical company's stock after buying an additional 520,637 shares during the quarter. Public Sector Pension Investment Board owned about 0.64% of TG Therapeutics worth $52,635,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the business. Morse Asset Management Inc acquired a new stake in TG Therapeutics during the 3rd quarter valued at approximately $29,000. EverSource Wealth Advisors LLC increased its stake in shares of TG Therapeutics by 51.9% in the first quarter. EverSource Wealth Advisors LLC now owns 1,068 shares of the biopharmaceutical company's stock worth $35,000 after acquiring an additional 365 shares during the period. Farther Finance Advisors LLC increased its stake in shares of TG Therapeutics by 45.8% in the third quarter. Farther Finance Advisors LLC now owns 993 shares of the biopharmaceutical company's stock worth $55,000 after acquiring an additional 312 shares during the period. Jacobi Capital Management LLC acquired a new stake in shares of TG Therapeutics in the third quarter worth $57,000. Finally, Signaturefd LLC increased its stake in shares of TG Therapeutics by 193.5% in the third quarter. Signaturefd LLC now owns 1,092 shares of the biopharmaceutical company's stock worth $61,000 after acquiring an additional 720 shares during the period. 58.58% of the stock is owned by hedge funds and other institutional investors.

TG Therapeutics Stock Up 5.4%

TGTX opened at $66.12 on Thursday. The company has a fifty day moving average of $57.20 and a two-hundred day moving average of $45.84. The stock has a market capitalization of $9.99 billion, a price-to-earnings ratio of 100.18, a PEG ratio of 4.94 and a beta of 1.89. TG Therapeutics, Inc. has a fifty-two week low of $26.76 and a fifty-two week high of $68.03. The company has a debt-to-equity ratio of 1.30, a quick ratio of 3.75 and a current ratio of 4.50.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its earnings results on Monday, November 9th. The biopharmaceutical company reported $0.35 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.36 by ($0.01). TG Therapeutics had a return on equity of 18.82% and a net margin of 11.81%. The firm had revenue of $259.94 million for the quarter, compared to analysts' expectations of $245.47 million. During the same period in the previous year, the company earned $2.43 earnings per share. The company's revenue was up 60.8% compared to the same quarter last year. On average, research analysts expect that TG Therapeutics, Inc. will post 1.10 earnings per share for the current year.

Insider Buying and Selling at TG Therapeutics

In related news, Director Laurence Charney sold 5,000 shares of the company's stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $54.96, for a total value of $274,800.00. Following the completion of the transaction, the director owned 168,640 shares of the company's stock, valued at approximately $9,268,454.40. This represents a 2.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 8.87% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms recently issued reports on TGTX. Weiss Ratings upgraded shares of TG Therapeutics from a "buy (b-)" rating to a "buy (b)" rating in a research report on Wednesday, November 4th. JPMorgan Chase & Co. upped their price target on shares of TG Therapeutics from $65.00 to $72.00 and gave the company an "overweight" rating in a report on Friday, August 7th. HC Wainwright reaffirmed a "buy" rating and issued a $78.00 price target on shares of TG Therapeutics in a report on Tuesday, September 1st. B. Riley Financial increased their price target on TG Therapeutics from $55.00 to $86.00 and gave the stock a "buy" rating in a research report on Monday, July 27th. Finally, Zacks Research upgraded TG Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $63.00.

Get Our Latest Report on TG Therapeutics

TG Therapeutics Company Profile

(Free Report)

TG Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for B-cell diseases, including autoimmune disorders and blood cancers. Its research has centered on therapies that target B cells, a type of immune cell involved in these conditions. The company's marketed product, BRIUMVI (ublituximab-xiiy), is an anti-CD20 monoclonal antibody approved in the United States to treat adults with relapsing forms of multiple sclerosis. TG Therapeutics also has investigated other drug candidates and combinations for immune-related and hematologic diseases.

Featured Articles

Want to see what other hedge funds are holding TGTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report).

Institutional Ownership by Quarter for TG Therapeutics (NASDAQ:TGTX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in TG Therapeutics Right Now?

Before you consider TG Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TG Therapeutics wasn't on the list.

While TG Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines